CM
CRL icon

Castleark Management’s Charles River Laboratories CRL Stock Holding History

Castleark Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.17M Sell
36,045
-3,390
-9% -$604K 0.22% 113
2026
Q1 		$6.8M Buy
39,435
+7,190
+22% +$1.33M 0.23% 114
2025
Q4 		$6.43M Buy
32,245
+980
+3% +$178K 0.19% 132
2025
Q3 		$4.89M Buy
+31,265
New +$4.97M 0.14% 148
2023
Q1 		– Sell
-4,220
Closed -$920K – 285
2022
Q4 		$920K Buy
+4,220
New +$922K 0.05% 202
2020
Q3 		– Sell
-39,670
Closed -$6.92M – 350
2020
Q2 		$6.92M Sell
39,670
-12,250
-24% -$1.96M 0.3% 99
2020
Q1 		$6.55M Buy
+51,920
New +$7.79M 0.39% 72
2017
Q4 		– Sell
-5,010
Closed -$541K – 410
2017
Q3 		$541K Hold
5,010
– – 0.02% 305
2017
Q2 		$507K Buy
+5,010
New +$461K 0.02% 306

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Castleark Management's CRL Position: Q2 2026 in Review

Castleark Management reduced its Charles River Laboratories (CRL) stake by 8.6% in Q2 2026, selling an estimated $604K and leaving 36,045 shares worth $8.17M. The position accounts for 0.22% of the portfolio, ranked #113.

Castleark Management first reported a position in CRL in Q2 2017 and has held it in 9 quarters since. 569 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Castleark Management held 36,045 shares of Charles River Laboratories worth $8.17M as of Q2 2026.
  • Castleark Management sold 3,390 Charles River Laboratories shares in Q2 2026, an estimated $604K.
  • Charles River Laboratories made up 0.22% of Castleark Management's portfolio in Q2 2026, its #113 holding.
  • Castleark Management first reported a position in Charles River Laboratories in Q2 2017 and has held it in 9 quarters since.
  • 569 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Castleark Management's 13F filing for Q2 2026, filed 14 Aug 2026.